-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
Advantages of InnoModels Biotechnology ELISA platform in detail
Author:
InnoModels
Release time:
2024-09-10
As a biotech company co-founded by scientists from Novo Nordisk China R&D Center, Sino-American Champion and Shanghai Jiao Tong University Institute of Immunology, InnoModels Biotechnology (Beijing) Co., Ltd. has demonstrated outstanding strength in biotechnology, especially in immunology and disease diagnostics. Among them, InnoModels' ELISA (Enzyme Linked Immunosorbent Assay) platform has been widely used and recognized in biomedical research, disease diagnosis and drug discovery and development with its unique advantages.
Sensitivity and Specificity
The primary advantage of the ELISA platform is its high sensitivity and specificity. In the ELISA method of enzyme activity amplification, the sensitivity of the assay far exceeds that of the traditional RIA (radioimmunoassay) technique, and is capable of capturing very low concentrations of target proteins or antibodies. This high degree of sensitivity not only ensures the accuracy of the test results, but also makes the platform valuable in applications such as early disease diagnosis and drug efficacy monitoring. Meanwhile, ELISA technology increases the specificity of the detection process through the specificity of the enzyme-substrate reaction, effectively avoiding the interference of non-specific signals.
Easy to operate and low cost
Another significant advantage of the ELISA platform is its simplicity and cost-effectiveness. Compared with other high-end detection technologies, ELISA experiments require relatively simple instruments and equipment, including a spiker, incubator, and enzyme-specific readers, which can be configured in an ordinary laboratory. In addition, the cost of ELISA kits is relatively low, and due to the stability of the reaction system, the reagents can be stored for a long time under low temperature or dry conditions, which reduces the cost of the experiment. What's more, the ELISA process is simple, with no need for complicated sample pre-treatment steps, and preliminary results can be obtained within minutes, greatly improving experimental efficiency.
Wide range of applications to meet diversified needs
InnoModels Bio's ELISA platform is not only limited to a specific field of application, but also demonstrates a wide range of adaptability. In biomedical research, ELISA technology can be used to quantitatively detect specific proteins or antibodies in serum, plasma or other body fluids, providing important data support for disease mechanism research and drug target screening. In the field of clinical diagnosis, ELISA platform can be used for early diagnosis, disease monitoring and prognosis assessment of various diseases. In addition, ELISA technology can be used to assess the impact of drugs on the immune system during drug development, providing an important basis for drug safety and efficacy evaluation.

Contributing to tumor and immunotherapy research
It is especially worth mentioning that with its stable domestic platforms for humanized immune system mice (HIS) and human tumor xenografts (PDX), InnoModels has a significant advantage in the field of oncology and tumor immunopharmacodynamics CRO services, and the combination of the ELISA platform and these platforms provides a new generation of experimental animal models that are close to the clinic for the research and development of oncology and tumor immunotherapies. The ELISA platform, in combination with these platforms, provides a new generation of experimental animal models close to the clinic for tumor and tumor immunotherapy research and development. In the fields of tumor vaccine research and immune checkpoint inhibitor development, the ELISA platform provides an important reference for the effectiveness and safety assessment of therapeutic methods by accurately detecting and analyzing the activity and number of specific immune cells in patients.
Conclusion
In summary, with its advantages of high sensitivity, high specificity, easy operation and high cost-effectiveness, InnoModels' ELISA platform has shown great potential for application in various fields such as biomedical research, disease diagnosis and drug discovery. In the future, with the continuous progress and innovation of technology, we believe that ELISA platform will play an important role in more fields and make greater contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd